MarketPeel
Insider Trading Intelligence
Pricing
…
KM

Kimberly Manhard

HRTX
EVP, DRUG DEVELOPMENT · HERON THERAPEUTICS, INC. /DE/ · CIK 0001202094
FILING MIX · LIFETIME50%/50%
BUYS
34
SELLS
34
TOTAL VALUE
$645.1K
COMPANIES
2
ACTIVE SINCE
Apr 2020
HOLDINGS NOW
44,747
AVG SELL PX
$12.00
TRADE KIND
SHOWING 68 / 68
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
5 backtested trades · 8 horizons · 1 pending
Forward-return performance of every backtestable P/S trade by Kimberly Manhard, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d5+40.00%-0.28%-0.19%-0.09%+1.22%—
14d5+80.00%-5.07%-0.18%-4.88%-2.04%—
30d5+80.00%-3.99%+3.22%-7.21%-19.31%—
60d5+80.00%-8.62%+3.22%-11.84%-14.15%—
90d5+80.00%-12.28%+6.86%-19.14%-33.03%—
180d5+60.00%-16.07%+8.71%-24.79%-18.18%—
1y5+80.00%-9.77%+19.37%-29.14%-50.60%—
2y5(1 pending)+100.00%-71.32%+20.83%-92.14%-90.59%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
HRTX · 29,747 shares · as of Apr 13, 2023
041,49082,981124,471165,961202120222023SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 34 buys / 34 sellsCOVERAGE · 25 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
INBX
INHIBRX BIOSCIENCES, INC.
PURCHASEGRANT
Stock grant
15,000——15,000Jun 3, 2026Jun 4, 2026 ↗View →
INBX
INHIBRX BIOSCIENCES, INC.
PURCHASEGRANT
Stock grant
15,000——15,000May 28, 2025May 29, 2025 ↗View →
INBX
INHIBRX BIOSCIENCES, INC.
PURCHASE
10,000$13.98$139.8K10,000Aug 28, 2024Aug 30, 2024 ↗View →
INBX
INHIBRX BIOSCIENCES, INC.
SALE
17,259——0May 30, 2024May 30, 2024 ↗View →
INBX
INHIBRX BIOSCIENCES, INC.
SALE
15,000——0May 30, 2024May 30, 2024 ↗View →
INBX
INHIBRX BIOSCIENCES, INC.
SALE
3,500——0May 30, 2024May 30, 2024 ↗View →
INBX
INHIBRX BIOSCIENCES, INC.
PURCHASEGRANT
Stock grant
15,000——15,000May 25, 2023May 30, 2023 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
EVP, Drug Development
1,417$2.88$4.1K28,330Apr 13, 2023Apr 17, 2023 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
EVP, Drug Development
1,250——7,500Apr 13, 2023Apr 17, 2023 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Drug Development
1,250——25,183Apr 13, 2023Apr 17, 2023 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
EVP, Drug Development
4,564——27,936Apr 13, 2023Apr 17, 2023 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Drug Development
4,564——29,747Apr 13, 2023Apr 17, 2023 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASEGRANT
Stock grant
149,365——149,365Jan 18, 2023Jan 20, 2023 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Drug Development
4,564——25,945Jan 13, 2023Jan 17, 2023 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Drug Development
1,250——21,381Jan 13, 2023Jan 17, 2023 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
EVP, Drug Development
4,564——32,500Jan 13, 2023Jan 17, 2023 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
EVP, Drug Development
2,012$3.17$6.4K23,933Jan 13, 2023Jan 17, 2023 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
EVP, Drug Development
1,250——8,750Jan 13, 2023Jan 17, 2023 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Drug Development
1,655$3.27$5.4K20,131Oct 31, 2022Jan 17, 2023 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
EVP, Drug Development
4,564——37,064Oct 13, 2022Oct 17, 2022 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
EVP, Drug Development
1,250——10,000Oct 13, 2022Oct 17, 2022 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Drug Development
1,250——15,924Oct 13, 2022Oct 17, 2022 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Drug Development
4,564——20,488Oct 13, 2022Oct 17, 2022 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
EVP, Drug Development
2,012$3.76$7.6K18,476Oct 13, 2022Oct 17, 2022 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASEGRANT
Stock grant
165,961——165,961Jul 25, 2022Jul 27, 2022 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Drug Development
1,250——12,122Jul 13, 2022Jul 15, 2022 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
EVP, Drug Development
4,564——41,628Jul 13, 2022Jul 15, 2022 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
EVP, Drug Development
2,012$3.01$6.1K14,674Jul 13, 2022Jul 15, 2022 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Drug Development
4,564——16,686Jul 13, 2022Jul 15, 2022 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
EVP, Drug Development
1,250——11,250Jul 13, 2022Jul 15, 2022 ↗View →
INBX
INHIBRX BIOSCIENCES, INC.
PURCHASEGRANT
Stock grant
15,000——50,759May 25, 2022May 26, 2022 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
EVP, Drug Development
1,504$4.76$7.2K10,872May 3, 2022May 4, 2022 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Drug Development
1,504$3.84$5.8K12,376Apr 29, 2022May 4, 2022 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
EVP, Drug Development
2,012$6.07$12.2K10,872Apr 13, 2022Apr 15, 2022 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Drug Development
4,564——12,884Apr 13, 2022Apr 15, 2022 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
EVP, Drug Development
4,564——46,192Apr 13, 2022Apr 15, 2022 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Drug Development
1,250——8,320Apr 13, 2022Apr 15, 2022 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
EVP, Drug Development
1,250——12,500Apr 13, 2022Apr 15, 2022 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Drug Development
4,564——9,082Jan 13, 2022Jan 14, 2022 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Drug Development
1,250——4,518Jan 13, 2022Jan 14, 2022 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
EVP, Drug Development
4,564——50,756Jan 13, 2022Jan 14, 2022 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
EVP, Drug Development
2,012$8.30$16.7K7,070Jan 13, 2022Jan 14, 2022 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
EVP, Drug Development
1,250——13,750Jan 13, 2022Jan 14, 2022 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
EVP, Drug Development
433$10.55$4.6K3,268Oct 13, 2021Oct 15, 2021 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASEGRANT
Stock grant
92,200——92,200Oct 13, 2021Oct 15, 2021 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASEGRANT
Stock grant
55,320——55,320Oct 13, 2021Oct 15, 2021 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Drug Development
1,250——3,701Oct 13, 2021Oct 15, 2021 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
EVP, Drug Development
1,250——15,000Oct 13, 2021Oct 15, 2021 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
EVP, Drug Development
1,250——16,250Jul 13, 2021Jul 15, 2021 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
EVP, Drug Development
433$13.48$5.8K2,451Jul 13, 2021Jul 15, 2021 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Drug Development
1,250——2,884Jul 13, 2021Jul 15, 2021 ↗View →
INBX
INHIBRX BIOSCIENCES, INC.
PURCHASEGRANT
Stock grant
15,000——35,759Jun 7, 2021Jun 8, 2021 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
EVP, Drug Development
1,529$17.66$27.0K1,634May 3, 2021May 4, 2021 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Drug Development
1,529$13.90$21.2K3,163Apr 30, 2021May 4, 2021 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Drug Development
1,250——2,067Apr 13, 2021Apr 15, 2021 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
EVP, Drug Development
1,250——17,500Apr 13, 2021Apr 15, 2021 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
EVP, Drug Development
433$16.66$7.2K1,634Apr 13, 2021Apr 15, 2021 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Drug Development
1,250——1,250Jan 13, 2021Jan 15, 2021 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
EVP, Drug Development
1,250——18,750Jan 13, 2021Jan 15, 2021 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
EVP, Drug Development
433$18.16$7.9K817Jan 13, 2021Jan 15, 2021 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
EVP, Drug Development
10,000——48,416Dec 22, 2020Dec 23, 2020 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
EVP, Drug Development
10,000$20.00$200.0K0Dec 22, 2020Dec 23, 2020 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
EVP, Drug Development
10,000$13.00$130.0K10,000Dec 22, 2020Dec 23, 2020 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASEGRANT
Stock grant
20,000——20,000Oct 13, 2020Oct 15, 2020 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASEGRANT
Stock grant
120,000——120,000Oct 13, 2020Oct 15, 2020 ↗View →
INBX
INHIBRX BIOSCIENCES, INC.
PURCHASEGRANT
Stock grant
17,259——17,259Aug 21, 2020Aug 21, 2020 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
Executive VP, Drug Development
1,158$13.97$16.2K0May 1, 2020May 1, 2020 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
Executive VP, Drug Development
1,158$12.12$14.0K1,158Apr 30, 2020May 1, 2020 ↗View →
Other insiders · HRTX
Loading peer insiders…
About this filer
CIK 0001202094
ROLE
EVP, Drug Development
PRIMARY
HRTX
COMPANIES
2
ACTIVE SINCE
Apr 2020
MARKETPEEL · /INSIDER/0001202094DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback